The PHI is a blood test that measures three forms of PSA to provide a more accurate assessment of prostate cancer risk and has been shown to improve prostate cancer detection accuracy, potentially reducing the number of unnecessary biopsies in up to a third of men [35]. The gene discussed is KLK3; the disease is prostate cancer.